Hub : Traits :

Worry (Nagel 2018)

935 significantly associated models · 142 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 117211384 118766534 1 1 1.7e-07 5.4e-09 2.8e-04 61 MAN1A2
2 1 153241677 154640423 1 1 5.6e-08 5.4e-07 1.4e-04 42 CREB3L4
3 1 226371939 227873074 2 1 6.6e-09 3.8e-08 4.2e-01 98 ADCK3
4 2 86483021 87126250 1 1 3.0e-07 1.4e-07 9.2e-02 90 VPS24
5 2 147993969 149475737 2 1 4.1e-11 7.7e-10 1.3e-01 94 ORC4L
6 3 16154636 17814553 1 1 1.2e-07 3.2e-06 2.0e-01 92 PLCL2
7 3 49598064 51398958 10 1 6.5e-11 1.9e-11 1.0e+00 100 U73166.2
8 3 51539688 54077726 20 1 5.5e-15 4.8e-12 1.4e-01 96 NEK4
9 3 84317575 86808226 1 1 2.9e-18 2.1e-19 1.0e+00 100 CADM2
10 3 135273949 137261517 5 1 5.2e-12 1.9e-11 4.7e-01 99 RP11-85F14.5
11 4 89947254 91439574 1 1 1.4e-09 2.6e-10 1.0e+00 100 SNCA
12 4 118707160 119423789 1 1 5.4e-09 1.7e-07 4.7e-02 86 NDST3
13 5 64272107 65711805 1 1 2.1e-07 7.5e-07 2.5e-01 94 SGTB
14 5 86867897 88429077 4 1 6.8e-10 3.6e-10 1.0e-04 62 TMEM161B
15 5 101762909 103244640 1 1 2.7e-08 1.4e-08 1.9e-01 95 PPIP5K2
16 8 9593924 10988275 1 1 9.6e-08 5.2e-09 1.5e-03 70 RP11-981G7.1
17 9 85627408 87026235 1 1 4.6e-08 6.3e-07 4.7e-02 84 RP11-522I20.3
18 9 95502571 96898436 1 1 8.2e-10 4.2e-09 3.8e-01 98 RP11-165J3.6
19 9 97520168 98975128 1 1 1.8e-08 5.7e-08 4.5e-01 98 PTCH1
20 9 127218258 128643415 2 1 1.2e-07 2.2e-07 1.0e+00 100 PRPS1P2
21 10 103550604 105910221 11 2 9.9e-14 2.9e-13 6.6e-01 100 AS3MT CALHM2
22 11 46578400 48559571 8 1 9.6e-14 3.3e-11 9.5e-01 100 MADD
23 11 112486568 113969669 3 2 6.6e-09 1.2e-09 3.7e-02 88 ANKK1 DRD2
24 12 49065727 50619618 1 1 2.8e-07 1.8e-06 7.2e-01 99 SPATS2
25 12 108763672 110704487 3 1 2.8e-10 2.4e-10 1.6e-01 95 MMAB
26 14 74424938 76239834 7 1 9.7e-14 1.2e-13 4.8e-03 86 RPS6KL1
27 16 29412503 31860399 15 2 4.2e-11 1.6e-08 2.0e-01 95 INO80E KAT8
28 17 19142226 20911204 3 1 7.2e-09 6.7e-08 1.5e-01 93 RP11-78O7.2
29 17 42607368 45796313 20 1 1.9e-14 8.6e-14 4.3e-01 99 MAPT
30 17 78843139 79380547 1 1 7.1e-09 2.2e-09 5.1e-02 89 AATK
31 18 30921425 31568499 1 1 8.8e-08 3.3e-08 1.0e-01 91 ASXL3
32 18 57349900 58729694 1 1 8.0e-08 4.9e-13 4.8e-07 52 MC4R
33 20 2496120 3897014 1 1 1.4e-07 5.0e-07 1.3e-02 76 ITPA
34 20 17776692 19441650 4 1 5.1e-09 1.1e-08 1.0e+00 100 DTD1
35 20 32594714 34109427 1 1 4.5e-09 2.8e-06 4.7e-01 98 NCOA6
36 22 40472399 42379813 3 1 5.4e-11 2.7e-10 4.5e-01 99 SLC25A17

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 2.6 1 0 0.0 0.00 1.0e+00 NEK4
Bipolar Disorder or Schizophrenia 3.8 6 4 8.9 0.98 7.0e-04 AS3MT INO80E NDST3 NEK4 PLCL2 SLC25A17
Depressed Affect (Nagel 2018) 7.6 15 9 20.0 0.98 1.4e-10 AATK ANKK1 ASXL3 DRD2 MADD MAPT MMAB ORC4L PLCL2 PTCH1 RP11-165J3.6 RP11-85F14.5 RPS6KL1 SNCA TMEM161B
Depression (Nagel 2018) 5.8 9 1 2.2 0.99 2.0e-07 AATK ANKK1 MADD MAPT PLCL2 RP11-165J3.6 RP11-85F14.5 SNCA U73166.2
Intelligence (Savage-Jansen 2018) 2.4 6 2 4.4 -0.80 5.6e-02 AATK MAPT NEK4 PLCL2 PPIP5K2 RP11-85F14.5
Neuroticism (Nagel 2018) 14.5 33 19 42.2 0.97 9.0e-21 AATK ADCK3 ANKK1 AS3MT ASXL3 CADM2 CALHM2 DRD2 DTD1 ITPA KAT8 MADD MAPT MC4R MMAB NCOA6 NDST3 NEK4 ORC4L PLCL2 PRPS1P2 PTCH1 RP11-165J3.6 RP11-85F14.5 RP11-981G7.1 RPS6KL1 SGTB SLC25A17 SNCA SPATS2 TMEM161B U73166.2 VPS24
Schizophrenia (2018) 3.9 5 2 4.4 0.96 8.1e-03 AS3MT INO80E NEK4 RP11-85F14.5 SLC25A17
Alzheimer’s Disease (including proxy) 2.0 2 0 0.0 0.00 1.0e+00 KAT8 MADD
Verbal and Numeric Reasoning (VNR) 2.4 4 2 4.4 -0.99 5.5e-03 MAPT NEK4 PLCL2 PPIP5K2
Breast Cancer 1.1 1 1 2.2 0.00 1.0e+00 MAPT
Ovarian Cancer 1.8 1 1 2.2 0.00 1.0e+00 MAPT
Age at First Birth 2.0 1 0 0.0 0.00 1.0e+00 CREB3L4
Bipolar Disorder (2011) 2.4 1 0 0.0 0.00 1.0e+00 NEK4
Body Mass Index (BMI) (2010) 2.5 2 1 2.2 0.00 1.0e+00 MADD MC4R
Coronary Artery Disease (CAD) 1.8 1 0 0.0 0.00 1.0e+00 AS3MT
Fasting Glucose 2.1 1 1 2.2 0.00 1.0e+00 MADD
HDL Cholesterol 1.9 1 1 2.2 0.00 1.0e+00 MMAB
Neuroticism (2016) 6.8 5 1 2.2 1.00 1.4e-04 DRD2 MADD MAPT SLC25A17 U73166.2
Primary Biliary Cirrhosis 1.5 1 0 0.0 0.00 1.0e+00 PLCL2
Rheumatoid Arthritis 1.3 1 0 0.0 0.00 1.0e+00 PPIP5K2
Schizophrenia (2014) 4.2 7 3 6.7 0.97 2.8e-04 AS3MT DRD2 INO80E NEK4 PLCL2 RP11-85F14.5 SLC25A17
Triglycerides 1.6 1 0 0.0 0.00 1.0e+00 NCOA6
Blood Eosinophil Count 1.4 6 4 8.9 -0.62 1.9e-01 INO80E MAPT NEK4 ORC4L PLCL2 SLC25A17
Blood Platelet Count 1.1 10 8 17.8 -0.06 8.7e-01 CREB3L4 KAT8 MADD MAN1A2 NCOA6 NEK4 RP11-78O7.2 RP11-85F14.5 RPS6KL1 U73166.2
Blood Red Count 2.4 9 6 13.3 0.73 2.6e-02 DRD2 INO80E KAT8 MAPT NCOA6 NEK4 PLCL2 PPIP5K2 TMEM161B
Blood White Count 1.1 8 5 11.1 -0.43 2.8e-01 AATK MADD MAPT PPIP5K2 PTCH1 RP11-78O7.2 RP11-85F14.5 TMEM161B
Heel T-Score 1.5 9 4 8.9 -0.10 7.9e-01 ADCK3 DTD1 INO80E MADD MAPT NCOA6 RP11-165J3.6 SLC25A17 SPATS2
BMI 3.4 10 7 15.6 -0.84 2.1e-03 ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R NEK4 RP11-165J3.6 VPS24
Height 1.6 19 13 28.9 -0.16 5.1e-01 AATK AS3MT CREB3L4 INO80E KAT8 MADD MAPT MC4R NCOA6 NDST3 NEK4 ORC4L PPIP5K2 PTCH1 RP11-165J3.6 RP11-522I20.3 RPS6KL1 SNCA U73166.2
Waist Hip Ratio (WHR) 2.7 7 5 11.1 0.77 4.1e-02 MAPT NEK4 PLCL2 PPIP5K2 PRPS1P2 RP11-85F14.5 U73166.2
Systolic Blood Pressure 3.0 9 6 13.3 0.63 7.0e-02 AS3MT CADM2 CALHM2 MADD MAPT ORC4L PRPS1P2 RP11-78O7.2 RPS6KL1
Smoking Status 4.0 6 3 6.7 -0.33 5.2e-01 AATK AS3MT CADM2 NEK4 PLCL2 PRPS1P2
Allergy or Eczema 1.4 2 2 4.4 0.00 1.0e+00 PLCL2 SLC25A17
Cardiovascular Disease 1.3 2 0 0.0 0.00 1.0e+00 AS3MT RP11-85F14.5
Hypothyroidism (self reported) 1.2 1 1 2.2 0.00 1.0e+00 PPIP5K2
Type 2 Diabetes (T2D) (2018) 1.6 1 0 0.0 0.00 1.0e+00 PPIP5K2
Lung FEV1/FVC ratio 1.8 6 2 4.4 -0.50 3.1e-01 ADCK3 INO80E KAT8 MAPT PTCH1 RPS6KL1
Lung FVC 2.7 4 2 4.4 0.27 7.3e-01 KAT8 MAPT PTCH1 U73166.2
Neuroticism 13.8 33 24 53.3 0.97 9.2e-21 AATK ADCK3 ANKK1 AS3MT ASXL3 CADM2 CALHM2 DRD2 DTD1 KAT8 MADD MAN1A2 MAPT MC4R MMAB NCOA6 NDST3 NEK4 ORC4L PLCL2 PRPS1P2 PTCH1 RP11-165J3.6 RP11-85F14.5 RP11-981G7.1 RPS6KL1 SGTB SLC25A17 SNCA SPATS2 TMEM161B U73166.2 VPS24
Chronotype (morning person) 1.7 2 1 2.2 0.00 1.0e+00 TMEM161B U73166.2
Hair Pigment 2.6 3 3 6.7 0.00 1.0e+00 ADCK3 NCOA6 SLC25A17
Tanning 5.1 3 2 4.4 0.00 1.0e+00 CADM2 NCOA6 NEK4
Hand grip strength (left) 3.0 7 3 6.7 -0.40 3.7e-01 ADCK3 AS3MT CADM2 INO80E MADD MAPT RPS6KL1
Number of treatments/medications taken 2.4 1 1 2.2 0.00 1.0e+00 RPS6KL1
Sensitivity / hurt feelings 7.6 11 3 6.7 0.97 6.4e-07 ANKK1 DRD2 MAPT MMAB NDST3 ORC4L PLCL2 PTCH1 RP11-165J3.6 RP11-85F14.5 TMEM161B
Frequency of depressed mood in last 2 weeks 5.5 9 0 0.0 1.00 5.9e-09 AATK ANKK1 DRD2 MADD MAPT PLCL2 RP11-165J3.6 RP11-85F14.5 U73166.2
Hearing difficulty/problems: Yes 1.5 2 0 0.0 0.00 1.0e+00 MAPT MMAB
Relative age of first facial hair 2.5 1 1 2.2 0.00 1.0e+00 MAPT
Systolic blood pressure, automated reading 2.3 4 2 4.4 0.54 4.6e-01 AS3MT MADD MAPT PRPS1P2
Diabetes (father) 1.7 1 0 0.0 0.00 1.0e+00 INO80E
Impedance of leg (right) 3.4 13 8 17.8 0.72 5.3e-03 ADCK3 AS3MT CADM2 INO80E MADD MAPT MC4R NCOA6 NEK4 PRPS1P2 PTCH1 RPS6KL1 U73166.2
Leg fat-free mass (left) 3.2 7 7 15.6 -0.73 6.1e-02 AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1
Trunk fat percentage 2.4 8 5 11.1 -0.43 2.9e-01 ANKK1 INO80E KAT8 MADD MAPT MC4R RPS6KL1 SLC25A17
Hand grip strength (right) 2.4 5 2 4.4 -0.56 3.3e-01 CADM2 INO80E MADD MAPT NDST3
Current tobacco smoking 3.0 4 1 2.2 0.61 3.9e-01 AATK AS3MT PRPS1P2 SLC25A17
Maternal smoking around birth 1.7 1 0 0.0 0.00 1.0e+00 AS3MT
Fed-up feelings 4.5 7 4 8.9 0.99 6.0e-06 DRD2 MADD MAPT ORC4L PLCL2 RP11-85F14.5 RPS6KL1
Frequency of unenthusiasm / disinterest in last 2 weeks 4.0 3 0 0.0 0.00 1.0e+00 DRD2 RP11-85F14.5 U73166.2
Relative age voice broke 2.2 1 1 2.2 0.00 1.0e+00 MAPT
Taking other prescription medications 2.5 1 1 2.2 0.00 1.0e+00 RPS6KL1
Age when periods started (menarche) 2.2 4 2 4.4 0.49 5.1e-01 INO80E MADD MAPT NEK4
Heel bone mineral density (BMD) T-score, automated (left) 1.4 2 0 0.0 0.00 1.0e+00 ADCK3 MAPT
High blood pressure 1.6 2 1 2.2 0.00 1.0e+00 MADD MAPT
Hayfever, allergic rhinitis or eczema 1.4 1 0 0.0 0.00 1.0e+00 PLCL2
Sitting height 1.9 6 4 8.9 0.02 9.7e-01 AATK MADD MAPT NCOA6 NEK4 PTCH1
Body mass index (BMI) 3.1 8 5 11.1 -0.93 8.6e-04 AS3MT CADM2 INO80E KAT8 MADD MC4R NEK4 VPS24
Impedance of leg (left) 3.3 12 9 20.0 0.82 1.1e-03 ADCK3 AS3MT CADM2 INO80E MADD MAPT MC4R NCOA6 NEK4 PRPS1P2 RPS6KL1 U73166.2
Leg predicted mass (left) 3.2 7 7 15.6 -0.73 6.1e-02 AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1
Trunk fat mass 2.6 8 5 11.1 -0.85 7.3e-03 ANKK1 AS3MT CADM2 INO80E KAT8 MADD MAPT MC4R
Waist circumference 3.3 7 5 11.1 -0.84 1.9e-02 ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R
Number of incorrect matches in round 2.7 3 0 0.0 0.00 1.0e+00 AS3MT INO80E NDST3
Past tobacco smoking 3.1 3 2 4.4 0.00 1.0e+00 AS3MT CADM2 PRPS1P2
Nervous feelings 11.6 23 12 26.7 0.99 8.9e-22 ADCK3 ANKK1 AS3MT ASXL3 CADM2 CALHM2 CREB3L4 DTD1 INO80E ITPA KAT8 MADD MAPT NCOA6 NEK4 ORC4L PRPS1P2 RP11-85F14.5 RPS6KL1 SLC25A17 SNCA TMEM161B U73166.2
Frequency of tenseness / restlessness in last 2 weeks 6.7 7 2 4.4 0.99 2.0e-05 AATK DRD2 MAPT MMAB NEK4 RP11-165J3.6 RP11-85F14.5
Hearing difficulty/problems with background noise 2.3 1 1 2.2 0.00 1.0e+00 MAPT
Hair/balding pattern: Pattern 2 1.7 1 0 0.0 0.00 1.0e+00 MAPT
Forced vital capacity (FVC) 2.6 3 2 4.4 0.00 1.0e+00 MAPT NDST3 PTCH1
Heel bone mineral density (BMD) T-score, automated (right) 1.3 2 0 0.0 0.00 1.0e+00 ADCK3 MAPT
Ever unenthusiastic/disinterested for a whole week 2.6 1 0 0.0 0.00 1.0e+00 MAPT
Qualifications: None of the above 1.8 3 1 2.2 0.00 1.0e+00 PLCL2 RP11-78O7.2 TMEM161B
Financial difficulties in last 2 years 1.9 1 0 0.0 0.00 1.0e+00 DRD2
Mouth/teeth dental problems 1.6 1 0 0.0 0.00 1.0e+00 MAPT
Fluid intelligence score 2.5 3 0 0.0 0.00 1.0e+00 MAPT PLCL2 PPIP5K2
Neuroticism score 12.1 24 15 33.3 0.99 1.3e-18 AATK ADCK3 ANKK1 ASXL3 DRD2 DTD1 MADD MAPT MC4R MMAB NCOA6 NDST3 ORC4L PLCL2 PRPS1P2 PTCH1 RP11-165J3.6 RP11-85F14.5 RPS6KL1 SLC25A17 SNCA TMEM161B U73166.2 VPS24
Weight 3.1 8 5 11.1 -0.86 6.6e-03 ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R TMEM161B
Impedance of arm (right) 3.1 11 6 13.3 0.73 1.0e-02 ADCK3 CADM2 INO80E MAPT MC4R NCOA6 NEK4 PRPS1P2 RP11-522I20.3 TMEM161B U73166.2
Arm fat percentage (right) 2.7 7 4 8.9 -0.78 3.9e-02 ANKK1 INO80E KAT8 MADD MC4R RP11-165J3.6 VPS24
Trunk fat-free mass 3.0 10 7 15.6 -0.75 1.2e-02 AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 RP11-78O7.2 RPS6KL1 TMEM161B
Hip circumference 3.1 7 6 13.3 -0.78 3.7e-02 AS3MT CADM2 INO80E KAT8 MADD MC4R PTCH1
Worrier / anxious feelings 11.2 24 10 22.2 0.99 2.6e-22 ADCK3 AS3MT CADM2 DTD1 INO80E KAT8 MAN1A2 MAPT MC4R MMAB NCOA6 NDST3 NEK4 ORC4L PLCL2 PPIP5K2 PRPS1P2 PTCH1 RP11-165J3.6 RP11-85F14.5 RPS6KL1 SLC25A17 TMEM161B U73166.2
Frequency of tiredness / lethargy in last 2 weeks 4.8 4 2 4.4 1.00 4.3e-03 AATK MMAB ORC4L RP11-165J3.6
Hair/balding pattern: Pattern 3 2.2 1 1 2.2 0.00 1.0e+00 MAPT
Number of live births 1.9 2 0 0.0 0.00 1.0e+00 CADM2 MAPT
Forced expiratory volume in 1-second (FEV1) 2.4 3 2 4.4 0.00 1.0e+00 MAPT NDST3 PTCH1
Noisy workplace 1.5 1 0 0.0 0.00 1.0e+00 MAPT
Qualifications: A levels/AS levels or equivalent 1.3 2 0 0.0 0.00 1.0e+00 MAPT NDST3
Mouth/teeth dental problems: Dentures 1.9 1 0 0.0 0.00 1.0e+00 ADCK3
Medication: Ibuprofen (e.g. Nurofen) 1.7 1 0 0.0 0.00 1.0e+00 MAPT
Prospective memory result 2.3 1 0 0.0 0.00 1.0e+00 PLCL2
Forced expiratory volume in 1-second (FEV1), Best measure 2.0 2 1 2.2 0.00 1.0e+00 MAPT PTCH1
Impedance of arm (left) 3.1 9 6 13.3 0.71 3.3e-02 CADM2 INO80E MAPT MC4R NEK4 PRPS1P2 RP11-78O7.2 TMEM161B U73166.2
Arm fat mass (right) 3.0 8 5 11.1 -0.83 1.0e-02 ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R VPS24
Trunk predicted mass 3.0 10 7 15.6 -0.75 1.2e-02 AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 RP11-78O7.2 RPS6KL1 TMEM161B
Standing height 1.6 13 9 20.0 -0.18 5.6e-01 AATK AS3MT INO80E MADD MAPT MC4R NCOA6 NEK4 PPIP5K2 PTCH1 RP11-165J3.6 RPS6KL1 SNCA
Tense / 'highly strung' 9.6 20 2 4.4 0.99 3.8e-16 AATK ADCK3 ANKK1 CADM2 CREB3L4 DRD2 DTD1 INO80E KAT8 MAPT NCOA6 NEK4 ORC4L RP11-165J3.6 RP11-78O7.2 RP11-85F14.5 RPS6KL1 SGTB SLC25A17 U73166.2
Seen doctor (GP) for nerves, anxiety, tension or depression 5.5 6 1 2.2 0.99 1.9e-04 ANKK1 ASXL3 DRD2 RPS6KL1 SGTB TMEM161B
Hair/balding pattern: Pattern 4 3.2 1 1 2.2 0.00 1.0e+00 MAPT
Birth weight of first child 1.6 1 0 0.0 0.00 1.0e+00 AS3MT
Peak expiratory flow (PEF) 2.2 2 1 2.2 0.00 1.0e+00 MAPT NDST3
Qualifications: O levels/GCSEs or equivalent 1.7 1 0 0.0 0.00 1.0e+00 PLCL2
Medication: Paracetamol 2.9 1 1 2.2 0.00 1.0e+00 MAPT
Headache pain in last month 2.9 1 1 2.2 0.00 1.0e+00 MAPT
Hypothyroidism/myxoedema (self-reported) 1.2 1 0 0.0 0.00 1.0e+00 PPIP5K2
Birth weight 1.9 2 1 2.2 0.00 1.0e+00 AS3MT PTCH1
Forced vital capacity (FVC), Best measure 2.4 2 2 4.4 0.00 1.0e+00 MAPT PTCH1
Body fat percentage 2.4 6 4 8.9 -0.45 3.7e-01 ANKK1 INO80E KAT8 MADD MC4R RPS6KL1
Leg fat percentage (right) 2.4 10 5 11.1 -0.42 2.2e-01 ANKK1 CADM2 INO80E KAT8 MADD MC4R NDST3 RP11-165J3.6 RPS6KL1 VPS24
Arm fat-free mass (right) 3.1 8 6 13.3 -0.77 2.6e-02 AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 TMEM161B
Comparative body size at age 10 3.8 5 4 8.9 -0.98 2.8e-03 CADM2 MADD MC4R RP11-165J3.6 U73166.2
Worry too long after embarrassment 6.7 8 3 6.7 0.98 2.8e-05 ANKK1 DRD2 MAPT MMAB NCOA6 PRPS1P2 RP11-85F14.5 SPATS2
Seen a psychiatrist for nerves, anxiety, tension or depression 4.2 1 0 0.0 0.00 1.0e+00 SGTB
Number of children fathered 1.7 1 1 2.2 0.00 1.0e+00 CADM2
Health satisfaction 2.3 1 0 0.0 0.00 1.0e+00 DRD2
Qualifications: College or University degree 2.0 4 1 2.2 -0.03 9.7e-01 CADM2 MAPT PPIP5K2 TMEM161B
Medication for pain relief, constipation, heartburn 3.0 3 1 2.2 0.00 1.0e+00 MAPT RP11-165J3.6 RPS6KL1
Neck or shoulder pain in last month 2.6 1 1 2.2 0.00 1.0e+00 ASXL3
Whole body fat mass 2.8 7 6 13.3 -0.84 1.7e-02 ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R
Leg fat mass (right) 2.9 9 6 13.3 -0.84 4.7e-03 ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R TMEM161B VPS24
Arm predicted mass (right) 3.0 8 6 13.3 -0.77 2.4e-02 AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 TMEM161B
Pulse rate, automated reading 1.5 2 0 0.0 0.00 1.0e+00 KAT8 ORC4L
Alcohol intake frequency. 3.5 6 5 11.1 -0.37 4.7e-01 CADM2 DRD2 INO80E MADD MAPT TMEM161B
Comparative height size at age 10 1.5 7 3 6.7 -0.52 2.3e-01 INO80E KAT8 MAPT NEK4 PTCH1 RPS6KL1 SNCA
Number of full sisters 1.6 1 0 0.0 0.00 1.0e+00 CADM2
Suffer from 'nerves' 10.0 14 4 8.9 0.98 2.2e-09 AATK ANKK1 AS3MT CADM2 DTD1 INO80E KAT8 MADD MAN1A2 MAPT MC4R NEK4 RP11-78O7.2 RPS6KL1
Overall health rating 2.8 3 0 0.0 0.00 1.0e+00 AATK ANKK1 RP11-165J3.6
Chest pain or discomfort 2.1 1 0 0.0 0.00 1.0e+00 ASXL3
Age at last live birth 1.7 1 0 0.0 0.00 1.0e+00 DTD1
Hypertension (Self-reported) 1.5 1 0 0.0 0.00 1.0e+00 MADD
Smoking status: Previous 2.4 1 1 2.2 0.00 1.0e+00 CADM2
Forced expiratory volume in 1-second (FEV1), predicted 1.6 1 0 0.0 0.00 1.0e+00 PTCH1
Whole body fat-free mass 3.1 9 7 15.6 -0.72 2.9e-02 AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 RPS6KL1 TMEM161B
Leg fat-free mass (right) 3.2 7 7 15.6 -0.72 6.8e-02 AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1
Arm fat percentage (left) 2.7 5 4 8.9 -0.80 1.1e-01 ANKK1 INO80E KAT8 MADD MC4R
Average weekly red wine intake 1.9 1 0 0.0 0.00 1.0e+00 TMEM161B
Handedness (chirality/laterality): Left-handed 1.6 1 1 2.2 0.00 1.0e+00 MAPT
Mood swings 7.0 9 6 13.3 0.99 1.6e-07 ANKK1 ASXL3 DRD2 MADD MAPT PLCL2 RPS6KL1 SLC25A17 SNCA
Loneliness, isolation 3.6 3 1 2.2 0.00 1.0e+00 MADD MAPT ORC4L
Mouth/teeth dental problems: Mouth ulcers 2.0 1 1 2.2 0.00 1.0e+00 MAPT
Smoking status: Current 3.1 2 1 2.2 0.00 1.0e+00 AATK AS3MT
Forced expiratory volume in 1-second (FEV1), predicted percentage 2.0 1 1 2.2 0.00 1.0e+00 MAPT
Whole body water mass 3.1 9 7 15.6 -0.72 2.9e-02 AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 RPS6KL1 TMEM161B
Leg predicted mass (right) 3.2 7 7 15.6 -0.72 6.8e-02 AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1
Arm fat mass (left) 3.1 8 6 13.3 -0.84 9.7e-03 ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R VPS24
Average weekly champagne plus white wine intake 2.0 1 0 0.0 0.00 1.0e+00 MAPT
Miserableness 5.9 8 3 6.7 0.98 1.2e-05 ANKK1 DRD2 MADD MAPT MMAB NDST3 ORC4L RP11-165J3.6
Guilty feelings 5.7 8 3 6.7 0.98 8.5e-06 AATK ANKK1 DRD2 MADD MAPT PTCH1 RPS6KL1 SPATS2
Medication: Blood pressure 1.5 1 1 2.2 0.00 1.0e+00 MAPT
Medication: Paracetamol 2.5 1 1 2.2 0.00 1.0e+00 MAPT
Illnesses of father: High blood pressure 1.4 1 0 0.0 0.00 1.0e+00 MADD
Ever smoked 3.0 4 1 2.2 -0.70 3.0e-01 AATK AS3MT CADM2 NEK4
Basal metabolic rate 3.2 9 7 15.6 -0.75 2.0e-02 AS3MT CADM2 INO80E KAT8 MC4R NCOA6 PRPS1P2 PTCH1 TMEM161B
Leg fat percentage (left) 2.4 9 4 8.9 -0.40 2.9e-01 ANKK1 CADM2 INO80E KAT8 MADD MC4R NDST3 RP11-165J3.6 RPS6KL1
Arm fat-free mass (left) 3.1 8 5 11.1 -0.76 2.9e-02 AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 TMEM161B
Irritability 5.4 7 3 6.7 0.99 3.5e-06 ANKK1 DRD2 MAPT MMAB NCOA6 ORC4L SLC25A17
Risk taking 2.8 2 1 2.2 0.00 1.0e+00 CADM2 RP11-85F14.5
Ever had prostate specific antigen (PSA) test 1.6 1 0 0.0 0.00 1.0e+00 TMEM161B
Diastolic blood pressure, automated reading 1.1 1 0 0.0 0.00 1.0e+00 MADD
Vascular/heart problems diagnosed by doctor 1.4 1 0 0.0 0.00 1.0e+00 MADD
Pain experienced in last month 2.6 2 0 0.0 0.00 1.0e+00 MAPT MMAB
Basal cell carcinoma (self-reported) 1.8 1 0 0.0 0.00 1.0e+00 NCOA6
Impedance of whole body 3.5 10 9 20.0 0.75 1.3e-02 ADCK3 AS3MT CADM2 INO80E MAPT MC4R NCOA6 NEK4 PRPS1P2 U73166.2
Leg fat mass (left) 3.0 8 6 13.3 -0.84 8.9e-03 ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R TMEM161B
Arm predicted mass (left) 3.1 8 7 15.6 -0.76 2.9e-02 AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 TMEM161B

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 18 0.52 2.0
GTEx Adipose Visceral Omentum 14 0.69 2.3
GTEx Adrenal Gland 10 0.69 2.2
GTEx Artery Aorta 23 0.77 2.2
GTEx Artery Coronary 15 1.27 2.3
GTEx Artery Tibial 19 0.51 2.1
GTEx Brain Caudate basal ganglia 7 0.76 2.3
GTEx Brain Cerebellar Hemisphere 12 0.81 2.2
GTEx Brain Cerebellum 15 0.76 2.2
GTEx Brain Cortex 10 0.97 2.4
GTEx Brain Frontal Cortex BA9 10 1.08 2.5
GTEx Brain Hippocampus 8 1.53 2.7
GTEx Brain Hypothalamus 5 0.85 2.2
GTEx Brain Nucleus accumbens basal ganglia 12 1.39 2.3
GTEx Brain Putamen basal ganglia 5 0.80 2.4
GTEx Breast Mammary Tissue 15 0.76 2.3
GTEx Breast Mammary Tissue (Male) 9 0.76 2.2
GTEx Breast Mammary Tissue (Female) 16 0.98 2.3
GTEx Cells EBV-transformed lymphocytes 16 1.13 2.4
GTEx Cells Transformed fibroblasts 22 0.52 2.1
GTEx Colon Sigmoid 15 1.03 2.2
GTEx Colon Transverse 21 1.02 2.4
GTEx Esophagus Gastroesophageal Junction 16 1.11 2.3
GTEx Esophagus Mucosa 24 0.72 2.2
GTEx Esophagus Muscularis 24 0.74 2.3
GTEx Heart Atrial Appendage 13 0.82 2.4
GTEx Heart Left Ventricle 12 0.78 2.3
GTEx Liver 10 1.40 2.5
GTEx Lung 23 0.80 2.2
GTEx Muscle Skeletal 18 0.62 2.2
GTEx Nerve Tibial 22 0.51 2.1
GTEx Ovary 11 1.21 2.5
GTEx Pancreas 12 0.74 2.2
GTEx Pituitary 15 1.35 2.4
GTEx Prostate 7 0.84 2.2
GTEx Skin Not Sun Exposed Suprapubic 18 0.73 2.2
GTEx Skin Sun Exposed Lower leg 22 0.61 2.1
GTEx Small Intestine Terminal Ileum 5 1.08 2.6
GTEx Spleen 11 0.78 2.4
GTEx Stomach 10 0.69 2.3
GTEx Testis 19 0.60 2.2
GTEx Thyroid 27 0.68 2.2
GTEx Uterus 8 1.41 2.4
GTEx Vagina 7 1.10 2.3
GTEx Whole Blood 10 0.50 2.2
METSIM Adipose 21 0.46 2.0
NTR Blood 7 0.29 2.0
ROSMAP Brain Pre-frontal Cortex 26 0.59 2.2
YFS Blood 11 0.24 1.9
CommonMind Brain Pre-frontal Cortex 14 0.26 2.0
The Cancer Genome Atlas Bladder Urothelial Carcinoma 9 0.55 2.1
The Cancer Genome Atlas Breast Invasive Carcinoma 14 0.32 1.9
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 5 0.46 1.9
The Cancer Genome Atlas Colon Adenocarcinoma 6 0.29 2.0
The Cancer Genome Atlas Esophageal Carcinoma 5 0.73 2.3
The Cancer Genome Atlas Glioblastoma Multiforme 7 0.69 2.1
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 14 0.51 2.0
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 17 0.42 1.9
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 9 0.44 2.0
The Cancer Genome Atlas Brain Lower Grade Glioma 11 0.26 1.9
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 4 0.36 2.0
The Cancer Genome Atlas Lung Adenocarcinoma 14 0.48 2.0
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 12 0.48 2.1
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 11 0.69 2.0
The Cancer Genome Atlas Pancreatic Adenocarcinoma 5 0.30 2.0
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 8 0.61 2.0
The Cancer Genome Atlas Prostate Adenocarcinoma 16 0.35 1.9
The Cancer Genome Atlas Rectum Adenocarcinoma 4 0.58 2.1
The Cancer Genome Atlas Soft Tissue Sarcoma 7 0.66 2.1
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.19 1.9
The Cancer Genome Atlas Stomach Adenocarcinoma 7 0.42 2.0
The Cancer Genome Atlas Testicular Germ Cell Tumors 7 0.55 2.1
The Cancer Genome Atlas Thyroid Carcinoma 20 0.39 1.9
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 2 0.39 1.9